" class="no-js "lang="en-US"> BeiGene Archives - Medtech Alert
Saturday, June 21, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China

BeiGene, a global biotechnology company, has announced the China National Medical Products Administration (NMPA) approved […]

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

BeiGene, a global biotechnology company, announced today that the last piece of structural steel will […]

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Leap Therapeutics, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that […]

BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

BeiGene, a global biotechnology company, today announced that the United States Food and Drug Administration […]

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

Antengene Corporation Limited (“Antengene“ SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more